

Asymptomatic Cerebrovascular, Cognitive Dysfunctions and Mood Changes in Systemic Lupus Patients

Thesis

*Submitted in partial fulfillment of the Master Degree
in Internal Medicine*

Presented by

Shaimaa Gamal Arafa

M.B.B.Ch

Under supervision of

Prof. Dr. Howaida Elsayed Mansour

*Professor of Internal Medicine and Rheumatology
Ain-Shams University*

Prof. Dr. Khalid Abou Alfotouh Ahmad

*Professor of Radiodiagnosis and Head of Magnetic resonance unit,
Ain-Shams University*

Dr. Caroline Samy Morad

*Lecturer of Internal Medicine and Rheumatology
Ain-Shams University*

**FACULTY OF MEDICINE
AIN SHAMS UNIVERSITY
2015**

الإعتلالات الدماغية و الإدراكية الغير ظاهرية والتغيرات المزاجية في مرضي الذئبة الحمراء

رسالة

توطئة للحصول على درجة الماجستير
في الأ أمراض الباطنة العامة

مقدمة من

الطبيبة/ شيماء جمال عرفة حسن

بكالوريوس الطب والجراحة

تحت إشراف:

أ.د. هويدا السيد منصور

استاذ امراض الباطنة العامة والروماتيزم والمناعة
كلية الطب- جامعة عين شمس

أ.د. خالد ابو الفتوح احمد

استاذ الأشعة التشخيصية ومدير وحدة الرنين المغناطيسي
كلية الطب- جامعة عين شمس

د. كارولين سامي مراد

مدرس امراض الباطنة العامة والروماتيزم
كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠١٥



فَالُوا سُبْحَانَكَ

لَا عِلْمَ لَنَا

إِلَّا مَا عَلَّمْتَنَا

إِنَّكَ أَنْتَ

الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة (الآية ٣٢)



Acknowledgments

*First, I would like to thank **Allah** a lot for Blessing this work until it has reached its end, as a part of his generous help throughout our life.*

*My profound thanks and deep appreciation to **Professor Dr. Howaida Elsayed Mansour** Professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University for his great support and advice, her valuable remarks that gave me the confidence and encouragement to fulfill this work,*

*I am also thankful to **Professor Dr. Khalid Abou Alfotouh Ahmad** Professor of Radiodiagnosis and Head of Magnetic resonance unit, Ain-Shams University for his valuable supervision, co-operation and direction that extended throughout this work,*

*I would like to direct my special thanks to **Dr. Caroline Samy Morad** Lecturer of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, for her invaluable help, fruitful advice, continuous support offered to me and guidance step by step till this essay finished.*

Finally my deep thanks to my family and my husband for supporting me throughout my life.

List of Content

	Page
LIST OF ABBREVIATIONS	I
LIST OF TABLES	IV
LIST OF FIGURES	VI
Introduction and Aim of the Work	1
REVIEW OF LITERATURE	5
Patients and Methods	61
Results	73
Discussion	113
Summary	125
Conclusion	127
Recommendations	128
References	129
Arabic Summary	--

List of Abbreviations

6-MP	6-mercaptopurine
Ab	Antibody
ACL	Aspartate aminotransferase
aCL	Anticardiolipin
ACR	The American College of Rheumatology
ACS	Acute confusional state
AED	Anti-Epileptic Drug
ALT	Alanine aminotransferase
ANA	Anti-Nuclear Antibody
anti-Rib-P	Anti-ribosomal P
APL	Antiphospholipid antibodies
APS	Antiphospholipid Syndrome
AST	Aspartate aminotransferase
BDI	Beck Depression Inventory
BILAG	British Isles Lupus Assessment Group index
BLys	B lymphocyte stimulator
C3d	Complement component 3 d
CD	Cluster of Differentiation
CNS	Central Nervous System
CES-D	Center for Epidemiologic Studies Depression Scale
CBC	Complete blood count
CSDD	Cornell Scale for Depression in Dementia
CSF	Cerebrospinal Fluid
CT	Computerized Tomography
CVD	Cerebrovascular disease
CXR	Chest X Ray
CYC	Cyclophosphamide
DNA	Deoxyribonucleic acid
dsDNA	Anti-double stranded deoxyribonucleic acid
DSM	Diagnostic and Statistical Manual Criteria for Major depression
DTI	Diffusion Tensor Imaging
DWI	Diffusion-weighted imaging
EEG	Electro Encephalo Gram
ESR	Erythrocyte sedimentation rate
EULAR	European League Against Rheumatism
Fc	Fragment crystallizable region

List of Abbreviations (Cont..)

FDA	Food and Drug Administration
GD S	Geriatric Depression Scale
GM	Grey matter
HAM-A	Hamilton Anxiety Rating Scale
HAM-D	Hamilton Depression Rating Scale
Hb	Hemoglobin
HDRS	Hamilton Depression Rating Scale
hep2	Human epidermoid carcinoma cell line 2
HLA	Human Leucocyte Antigen
IBM	The International Business Machines Corporation
IFN	Interferon
IgG	Immunoglobulin G
IgM	Immunoglobulin G
IL	Interlukin
INR	International Normalized Ratio
IVIG	Intravenous immunoglobulin
JCV	John Cunningham virus
LAC	Lupus anticoagulant antibodies
LN	Lupus Nephritis
MCP-1	Monocyte chemoattractant protein-1
MDI	Major Depression Inventory
MMF	Mycophenolate mofetil
MMSE	Mini mental state examination
MPA	Mycophenolic acid
MR	Magnetic resonance
MRA	Magnetic resonance Angiograph
MRI	Magnetic resonance imaging
MRS	Magnetic resonance spectroscopy
MS	Multiple Sclerosis
MTI	Magnetic Transfer imaging
NCS	Nerve conduction studies
NMDA	N-methyl-D-aspartate
NMDAR	N-methyl-D-aspartate receptor
NP	Neuropsychiatric
NPSLE	Neuropsychiatric Systemic lupus erythematosus
NR2	N-methyl-D-aspartate Receptor 2

List of Abbreviations (Cont..)

NSAIDs	Nonsteroidal anti-inflammatory drugs
P value	Probability value
P/C	Protien /creatinine ratio
PCR	Polymerase Chain Reaction
PET	Positron emission tomography
PGA	Patient Global Assessment
PHQ	Patient Health Questionnaire
PLT	Platelets
PT	Prothrombin time
PTT	Partial thromboplastine time
QQ	Quantile-Quantile
RNA	Ribonucleic acid
S.cr	Serum creatinine
SD	Standard Deviation
SDS	Self-Rating Depression Scale
SLE	Systemic lupus erythematosus
SLEDAI	Systemic Lupus Erythematosus Disease Activity Index
SLICC	Systemic Lupus International Collaborating Clinics
SMMSE	Standardized Mini-Mental State Examination
SPECT	Single-photon emission computed tomography
SPSS	Statistical Package for the Social Sciences
<i>STAT4</i>	Signal Transducer and Activator of Transcription protein 4
TCD	Transcranial duplex
TIA	Transient Ischemic Attack
TNF	Tumor necrosis factor
TPI	Triosphosphate isomerase
<i>TREX1</i>	Three prime repair exonuclease 1
U/S	Ultrasound
Vs	Versus
WBC	White blood cell
WM	White matter

List of Table

Table	Title	Page
1-	Neuropsychiatric Syndromes of SLE	6
2-	Suggested approach to attributing neuropsychiatric event to systemic lupus erythematosus.	40
3-	SLEDAI Score	63
4-	mini-mental state examination	66
5-	Descriptive statistics of the data of SLE patients (n=30).	75
6-	Description of nephritis among SLE patients (n=30).	76
7-	Description of radiological data among SLE patients (n=30).	77
8-	Description of neuropsychiatric manifestations (NP) among our SLE patients (n=30).	77
9-	Description of MRI findings among SLE patients (n=30)	80
10-	Description of MRI Abnormalities	80
11-	Description of Magnetic Resonance Angiography (MRA) findings among SLE patients (n=30).	83
12-	Description of Magnetic Resonance Angiography (MRA) Abnormalities	83
13-	Antiphospholipid antibodies (APL) among SLE patients (n=30).	85
14-	Comparison between SLE patients with and without depression regarding MRI findings (n=30).	86
15-	Comparison between SLE patients with and without anxiety regarding MRI finding (n=30).	87
16-	Comparison between SLE patients with and without dementia regarding MRI finding (n=30).	88
17-	Comparison between SLE patients with and without APL regarding MRI finding. (n=30).	89
18-	Comparison between SLE patients with and without, depression, anxiety and dementia regarding MRA findings(n=30).	90
19-	Comparison between SLE patients with and without APL regarding MRA findings (n=30).	91

List of Table (Cont...)

Table	Title	Page
20-	Comparison between SLE patients with and without APL antibodies regarding, depression, anxiety and dementia (n=30).	92
21-	Comparison between patients with and without NPSLE with the other studied parameters. (n=30).	93
22-	comparison between SLE patients with and without nephritis regarding MRI findings. (n=30).	95
23-	Comparison between SLE patients with normal and abnormal MRI findings with the other studied parameters. (n=30).	96
24-	Comparison between SLE patients with normal and abnormal MRA findings regarding the other studied parameters. (n=30).	98
25-	Comparison between SLE patients with positive and negative APL antibodies regarding the other studied parameters. (n=30).	99
26-	Comparison between SLE patients with and without anxiety and the other NPSLE manifestations. (n=30).	101
27-	Comparison between SLE patients with and without depression with the other NPSLE manifestations(n=30).	102
28-	Comparison between SLE patients with and without dementia with the other NPSLE manifestations. (n=30)	103
29-	Comparison between SLE patients with normal and abnormal CXR findings regarding the other NPSLE manifestations(n=30)	104
30-	Comparison between SLE patients with and without nephritis regarding the other studied parameters(n=30)	106
31-	Correlations between HAM-D, HAM-A and SMMSE with the other studied parameters.	107

List of Figures

No.	Figure	Page
1-	NPSLE with Thrombotic Cerebrovascular Disease.	33
2-	NPSLE with Epilepsy and Sudden Death.	34
3-	SLICC classification Criteria for SLE	62
4-	Pie chart of depression among our SLE patients.	78
5-	Pie chart of anxiety among our SLE patients.	79
6-	Pie chart of dementia among our SLE patients.	79
7-	MRI of the brain showing tiny lacunar infarction is seen at left watershed zone	81
8-	MRI of the brain showing bilateral patchy small areas of cerebral ischemic white matter foci	81
9-	MRI of the brain showing bilateral patchy small areas of periventricular ischemic white matter foci	81
10	Pie chart of MRI findings among SLE patients (n=30).	82
11	MRA of the brain showing attenuated posterior cerebral circulation	83
12-	Pie chart of MRA findings among SLE patients (n=30).	84
13-	Description of antiphospholipid antibodies (APL) among SLE patients (n=30).	85
14-	Comparison between SLE patients with and without depression regarding MRI findings.	86
15-	Comparison between SLE patients with and without anxiety regarding MRI finding.	87
16-	Comparison between SLE patients with and without dementia regarding MRI finding.	88
17-	Comparison between SLE patients with and without APL regarding MRI finding.	89

List of Figures

No.	Figure	Page
18-	Comparison between SLE patients with and without depression regarding MRA findings.	90
19-	Significant positive correlation was found between HAM-A and HAM-D.	108
20-	Significant negative correlation was found between MMSE and HAM-D.	109
21-	Significant negative correlation was found between age and HAM-D	109
22-	Significant positive correlation was found between SLEDAI and HAM-D.	110
23-	Significant positive correlation was found between SLEDAI and HAM-A.	110
24-	Significant negative correlation was found between SMMSE and HAM-A.	111
25-	Significant negative correlation was found between SLEDAI and SMMSE.	111
26-	Significant negative correlation was found between P/C and Hb.	112

INTRODUCTION

Systemic lupus erythematosus (SLE) is a prototype of the systemic autoimmune connective tissue diseases. It affects 1 out of 2000 individuals worldwide of whom $\approx 90\%$ are women. SLE is characterized by a storm of auto-antibodies and the release of inflammatory cytokines to most body tissue organs (*Berthier and Kretzler, 2012*).

Although the specific cause of SLE is unknown, the development of the disease is the net result of the interplay of multiple factors including: genetic, ethnic, immuno-regulatory, hormonal and environmental factors (*Rahman and Isenberg, 2008*).

Recently, several studies have indicated that the leading cause of morbidity and mortality in SLE patients is due to wide spread accelerated atherosclerosis and cerebrovascular diseases which are the pathological background of the neuropsychiatric (NP) SLE syndrome (*Colombo and Cacciapaglia, 2009*).

A combination of chronic inflammatory and immune mediated mechanisms resulting in altered lipoprotein metabolism and the formation of proinflammatory and pro-oxidative lipids (*Jara and Medina, 2006*).

Contributory factors to accelerated atherosclerosis in SLE patients include increased levels of oxidized lipids, upregulation of adhesion molecules, and cytokines such as monocyte chemoattractant protein-1(MCP-1), tumor necrosis

factor (TNF), interferon- γ (IFN- γ), interleukin-1 (IL-1), and IL-12. Auto-antibodies are formed against the oxidized lipids and immune complexes in SLE patients, these antibodies play a role in the development of atherosclerosis in these patients (*McMahon and Hahn, 2007*).

The overall survival of SLE patients has significantly improved over the last 50 years, from 74.8 to 94.8% and from 63.2 to 91.4%; 5-year and 10-year survival, respectively (*Mak and Cheung, 2012*).

Neuropsychiatric (NP) disease occurs in as many as 30 – 56 % of all SLE patients. However, the diagnosis of neuropsychiatric SLE (NPSLE) remains difficult (*Unterman and Nolte, 2011*).

NP lupus is associated with significantly increased morbidity and mortality in SLE patients. In 1999, the American College of Rheumatology (ACR) defined 19 distinct neuropsychiatric syndromes in SLE, including psychosis and depression (*Ainiala and Hietaharju 2001*).

NP lupus is usually overlooked by the other more symptomatic disease manifestations, especially lupus nephritis (LN) which usually consumes the great clinical and laboratory concern. Subclinical NP lupus may be present early in the disease, however lack of the disease clinical signs and patients' unawareness delay the diagnosis "by the time we are argued regarding which immunosuppression should we use for LN remission induction, one should start cyclophosphamide for subclinical NP SLE (*Petri and Orbai, 2012*).

Recent data has suggested that both renal and neuropsychiatric lupus disease negatively affect the overall 5-year survival rate, whereas the neuropsychiatric involvement did not change the 10-year survival rate(*Mak and Cheung, 2012*).

In studies where patients were screened with formal neuropsychiatric and sensitive psychiatric testing, the prevalence of mood disorder and cognitive impairment was high. Mild cognitive impairment was the most frequent abnormality among these patients, with only 3–5 % exhibiting severe cognitive impairment (*Bertsias et al., 2010*).